ID   UM-UC-2
AC   CVCL_8155
SY   UM-UC2; UMUC2; UC-2; University of Michigan-Urothelial Carcinoma-2
DR   BTO; BTO:0006290
DR   BioSample; SAMN03151953
DR   cancercelllines; CVCL_8155
DR   Cosmic; 846277
DR   Cosmic; 1302357
DR   Cosmic; 2037968
DR   GEO; GSM136237
DR   Wikidata; Q54990987
RX   PubMed=3761468;
RX   PubMed=6471236;
RX   PubMed=16469639;
RX   PubMed=18812553;
RX   PubMed=19375735;
RX   PubMed=20143388;
RX   PubMed=24018021;
RX   PubMed=25997541;
RX   PubMed=26621286;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=19375735; PubMed=20143388). Originally thought to originate from a 61 year old male patient with a ureter transitional cell carcinoma.
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00281.
CC   Population: Caucasian; Swedish.
CC   Doubling time: 22 hours (PubMed=3761468).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=3761468; DOI=10.1016/S0022-5347(17)45139-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q., Wilson G.N., Cox B.;
RT   "Improved growth of human urothelial carcinoma cell cultures.";
RL   J. Urol. 136:953-959(1986).
//
RX   PubMed=6471236; DOI=10.1016/S0022-5347(17)49883-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q.;
RT   "UM-UC-1 and UM-UC-2: characterization of two new human transitional
RT   cell carcinoma lines.";
RL   J. Urol. 132:834-837(1984).
//
RX   PubMed=16469639; DOI=10.1016/S0022-5347(05)00323-X;
RA   Sabichi A.L., Keyhani A., Tanaka N., Delacerda J., Lee I.-L., Zou C.-P.,
RA   Zhou J.-H., Benedict W.F., Grossman H.B.;
RT   "Characterization of a panel of cell lines derived from urothelial
RT   neoplasms: genetic alterations, growth in vivo and the relationship of
RT   adenoviral mediated gene transfer to coxsackie adenovirus receptor
RT   expression.";
RL   J. Urol. 175:1133-1137(2006).
//
RX   PubMed=18812553; DOI=10.1093/jnci/djn304;
RA   Park H.-S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S.,
RA   Spiess P.E., Steinberg J.R., Wang Z., Katz R.L., Dinney C.P.N.,
RA   Elias K.J., Lotan Y., Naeem R.C., Baggerly K., Sen S., Grossman H.B.,
RA   Czerniak B.;
RT   "Quantitation of Aurora kinase A gene copy number in urine sediments
RT   and bladder cancer detection.";
RL   J. Natl. Cancer Inst. 100:1401-1411(2008).
//
RX   PubMed=19375735; DOI=10.1016/j.juro.2009.01.108;
RA   Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.;
RT   "The use of short tandem repeat profiling to characterize human
RT   bladder cancer cell lines.";
RL   J. Urol. 181:2737-2748(2009).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26621286; DOI=10.1186/s12864-015-2227-4;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a
RT   genomic resource for functional studies.";
RL   BMC Genomics 16:1019.1-1019.2(2015).
//